New Products: Agilent's ClearSeq AML, Emory's Pan-Ethnic Carrier Screen Test | GenomeWeb

Agilent Technologies has launched ClearSeq AML, a next-generation sequencing-based panel that targets 48 exons in 20 of the most commonly mutated genes in acute myeloid leukemia. Agilent researchers designed the panel in collaboration with Robert Ohgami and Daniel Arber at Stanford University. The panel provides 99.9 percent design coverage of targeted exons, according to the company and is based on its SureSelect and HaloPlex technology.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.